-
06-12-2019, 09:43 AM
#12731
Originally Posted by Beagle
Would be good if HGH got out in front of this with say a $150m preference share issue. Heck if Synlait can raise deeply subordinated and unsecured 5 year debt at 3.7% then I don't see why HGH would need to pay any more than that for preference shares.
They seem to have it under control all by themselves Beagle. Amazing eh !
https://www.nzx.com/announcements/345500
-
10-12-2019, 02:59 PM
#12732
Junior Member
Having trouble finding HGH ASX listing on Yahoo Finance, any ideas?
-
10-12-2019, 04:13 PM
#12733
Originally Posted by NADZAB
Having trouble finding HGH ASX listing on Yahoo Finance, any ideas?
hgh.ax or HGH.AX works for me.
-
10-12-2019, 04:18 PM
#12734
Originally Posted by NADZAB
Having trouble finding HGH ASX listing on Yahoo Finance, any ideas?
Pays to keep track of HGH.AX
Been $1.46 since that transaction of 1 share in August this year
Just listed for window dressing eh percy
”When investors are euphoric, they are incapable of recognising euphoria itself “
-
10-12-2019, 04:27 PM
#12735
Originally Posted by winner69
Pays to keep track of HGH.AX
Been $1.46 since that transaction of 1 share in August this year
Just listed for window dressing eh percy
No so.
A very important listing for HGH, as it gives them access to Australian institutions, who otherwise would not be allowed to support HGH's funding requirements.Not only that, but any Australian fund can also invest in HGH,although most will be on NZ registry for liquidity reasons, they are still investing in an ASX listed company.
Whether any trade or not does not matter.
Last edited by percy; 10-12-2019 at 04:32 PM.
-
10-12-2019, 04:30 PM
#12736
Originally Posted by percy
No so.
A very important listing for HGH as it gives them access to Australian institutions, who otherwise would not be allowed to support HGH's funding requirements.
That’s what I meant by window dressing
It’s not there for the likes of nadzab
”When investors are euphoric, they are incapable of recognising euphoria itself “
-
10-12-2019, 04:37 PM
#12737
Originally Posted by percy
No so.
A very important listing for HGH, as it gives them access to Australian institutions, who otherwise would not be allowed to support HGH's funding requirements.Not only that, but any Australian fund can also invest in HGH,although most will be on NZ registry for liquidity reasons, they are still investing in an ASX listed company.
Whether any trade or not does not matter.
Well no reason NADZAB can't trade HGH on ASX.Liquidity would be a problem though.Could possibly be the odd chance of currency arbitrage.
Yes window dressing,but very important window dressing.
-
10-12-2019, 08:21 PM
#12738
Junior Member
So Today - NZX 1.70NZD/ASX 1.46AUD thats roughly a 16% difference.
- AUD/NZD pair today 4% difference
- Am I missing something.....
- As of today 12% cheaper to buy on ASX
- Transaction cost cheaper on ASX
- Dividend payment 6.54% on ASX / 5.81% NZX (due to cheaper share price)
- If I am a non tax resident of AUZ&NZ the ASX would be the best exchange to buy on assuming I can buy them on ASX for this price.
-
10-12-2019, 08:27 PM
#12739
Originally Posted by NADZAB
So Today - NZX 1.70NZD/ASX 1.46AUD thats roughly a 16% difference.
- AUD/NZD pair today 4% difference
- Am I missing something.....
- As of today 12% cheaper to buy on ASX
- Transaction cost cheaper on ASX
- Dividend payment 6.54% on ASX / 5.81% NZX (due to cheaper share price)
- If I am a non tax resident of AUZ&NZ the ASX would be the best exchange to buy on assuming I can buy them on ASX for this price.
That $1.46 was the price for the last sale ....1 share on August 31st ......no sales since then
Today there are no sellers ...none whatsoever ...hasn’t been for zonks but somebody offering to buy at 154
As percy said no liquidity for Hgh on the ASX ...need that to do what you want to do
Put a bid in ...you never know
”When investors are euphoric, they are incapable of recognising euphoria itself “
-
10-12-2019, 10:17 PM
#12740
"ANZ NZ is staying mum on a report it may be again trying to sell finance company UDC. The Australian reports an ANZ sale of UDC could be on again with Morgan Stanley acting as an advisor. Asked about this an ANZ NZ spokeswoman told interest.co.nz; "We don’t comment on market speculation so won’t be making a comment here." In its annual results announcement in October ANZ said it was again exploring a range of strategic options, including divestment, for UDC."
I don't have a subscription to the Australian, but from the free sample at the top of the article, "All the parties lining up are understood to be private equity firms".
https://www.interest.co.nz/news/1029...ter-trend-weak
https://www.theaustralian.com.au/bus...7a928b3c2872dc (for those with a subscription)
Last edited by mfd; 10-12-2019 at 10:19 PM.
Reason: formatting
Tags for this Thread
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks